GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck KGaA (WBO:MRCK) » Definitions » 3-Year EPS without NRI Growth Rate

Merck KGaA (WBO:MRCK) 3-Year EPS without NRI Growth Rate : 15.80% (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Merck KGaA 3-Year EPS without NRI Growth Rate?

Merck KGaA's EPS without NRI for the three months ended in Sep. 2024 was €1.86.

During the past 12 months, Merck KGaA's average EPS without NRI Growth Rate was -14.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was 15.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 25.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was 8.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Merck KGaA was 48.90% per year. The lowest was -16.70% per year. And the median was 7.50% per year.


Competitive Comparison of Merck KGaA's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Merck KGaA's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck KGaA's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck KGaA's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Merck KGaA's 3-Year EPS without NRI Growth Rate falls into.



Merck KGaA 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Merck KGaA  (WBO:MRCK) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Merck KGaA 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Merck KGaA's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Merck KGaA Business Description

Industry
Address
Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (44% of 2023 sales) primarily provides laboratory consumables and services to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (38%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (17%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.

Merck KGaA Headlines

No Headlines